bioAffinity Technologies BIAF
NASDAQ BIAF
$5.10 +0.02 (+0.39%)
As of: Aug 27, 2026 · 3:59 PM EDT

bioAffinity Technologies (BIAF) Convertible Debt (2021 - 2022)

bioAffinity Technologies (BIAF) posted quarterly Convertible Debt of $325000.0 for Q4 2022, down 87.5% year-over-year from $2.6 million in Q4 2021, and down 87.5% quarter-over-quarter from $2.6 million in Q3 2022.

bioAffinity Technologies (BIAF) Convertible Debt (2021 - 2022) Analysis & Trends

bioAffinity Technologies (BIAF) has reported Convertible Debt for 2 consecutive years, with $325000.0 the latest figure, recorded in Q4 2022.

  • In Q4 2022, Convertible Debt fell 87.5% year-over-year to $325000.0; the TTM figure through Dec 2022 stood at $325000.0 (down 87.5% YoY), while the FY2022 annual figure was $325000.0, down 87.5% from the prior year.
  • Convertible Debt slipped to $325000.0 in Q4 2022 per BIAF's latest filing, from $2.6 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $2.6 million in Q4 2021 and bottomed at $325000.0 in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 234.15 Bn 230.09 Bn 8.34 Bn
2 Danaher 152.10 Bn 147.75 Bn 3.61 Bn
3 Natera 48.48 Bn 47.38 Bn 486.15 Mn
4 Agilent Technologies 44.35 Bn 42.55 Bn 990.00 Mn
5 Iqvia Holdings 43.68 Bn 41.60 Bn 1.44 Bn
6 Idexx Laboratories 43.02 Bn 42.83 Bn 779.09 Mn
7 Illumina 34.39 Bn 33.22 Bn 770.00 Mn
8 Mettler Toledo International 28.29 Bn 28.24 Bn 650.22 Mn
9 Labcorp Holdings 27.51 Bn 27.37 Bn 1.11 Bn
10 bioAffinity Technologies 1.78 Mn -649,139.45 -

Historic Data

Download Data
DateValue
Dec 31, 2022 325,000.00
Sep 30, 2022 2.60 Mn
Mar 31, 2022 2.60 Mn
Dec 31, 2021 2.60 Mn
Sep 30, 2021 900,000.00